Remove clinical endocrinology
article thumbnail

VBC enabler Valendo Health launches for endocrinologists to provide 'across the board' diabetes care

Fierce Healthcare

A new value-based care enabler focused on endocrinology has launched with a mission to shape the future of diabetes care. Valendo Health uses a phased approach to offer expertise, technology and data-rich tools to help independent physicians enhance clinical capacity, streamline operations and transition to value-based care.

104
104
article thumbnail

Novel medicine could address short stature in children

European Pharmaceutical Review

[vosoritide] is the first medicine that has been developed to specifically target the pathway involved in hypochondroplasia” “This is the first medicine that has been developed to specifically target the pathway involved in hypochondroplasia,” commented Dr Andrew Dauber, Chief of Endocrinology at Children’s National Hospital in the US.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How long does testosterone take to work?

The Checkup by Singlecare

“The timeframe for experiencing the effects of TRT varies depending on individual factors and the type of administration,” explains Linda Khoshaba , NMD, founder of Natural Endocrinology Specialists (NES) in Scottsdale, Arizona. Generally, TRT will begin to work gradually, with symptoms appearing over the duration of treatment.

Labelling 105
article thumbnail

Rhythm buys Dutch biotech company Xinvento

Pharmaceutical Technology

The acquisition of Xinvento is a solid strategic fit with the rare endocrinology focus of Rhythm and is expected to offer new development opportunities. In two short years, we believe she has driven a nimble, science-focused organisation towards bringing a highly promising therapeutic candidate into the clinic. “We

52
article thumbnail

Sanofi treatment could slow type 1 diabetes progression

European Pharmaceutical Review

Data from the Phase III PROTECT clinical trial , presented at the 2023 Annual ISPAD Conference, showed that superior beta cell preservation was observed compared to placebo. HbA1c reductions and the overall rates of clinically important hypoglycemic events were similar among both study groups. As the primary endpoint, 94.9

110
110
article thumbnail

Weekly injection shows promise for type 1 diabetes

European Pharmaceutical Review

Insulin icodec, a once-weekly basal injection to treat type 1 diabetes, has the potential to be as effective in managing the condition as daily basal insulin treatments, according to results of the year-long ONWARDS 6 Phase IIIa clinical trial, recently published in the Lancet. Funding was provided by Novo Nordisk.

98
article thumbnail

Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin

Pharma Mirror

The DREAM study is an observational, non-pharmacologic and non-interventional clinical study initiated by certain researchers participating in the. The post Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin appeared first on Pharma Mirror Magazine.